Literature DB >> 3398357

Serum and cerebrospinal fluid vitamin B12 levels in demented patients with CH3-B12 treatment--preliminary study.

Y Mitsuyama1, H Kogoh.   

Abstract

The vitamin B12 (VB12) parameter was studied in the serum and cerebrospinal fluid (CSF) of 14 demented patients. Eleven of these patients were in a state of dementia of the degenerative type such as Alzheimer's disease, senile dementia and Pick's disease. The serum VB12 concentration in all the patients was within normal limits, i.e. 500-1,300 pg/ml. There was no significant difference between the CSF-VB12 levels and the severity of dementia. The serum and CSF-VB12 levels of the demented patients did not show any significant elevation after the oral administration of CH3-B12, 2 mg per day. On the other hand, there was a marked elevation of both the serum and CSF-VB12 after an oral medication (2 mg per day) plus intramuscular administrations (500 micrograms per day). These results confirm that the intramuscular administration of CH3-B12 is an effective way to get a higher value of the serum and CSF-VB12 levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3398357

Source DB:  PubMed          Journal:  Jpn J Psychiatry Neurol        ISSN: 0912-2036


  4 in total

1.  Influence of vitamin B12 on brain methionine adenosyltransferase activity in senile dementia of the Alzheimer's type.

Authors:  C Gomes-Trolin; C G Gottfries; B Regland; L Oreland
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Assessment of Vitamin B12 Deficiency and Risk Factors in Healthy Infants.

Authors:  Kuchana Suresh Kumar; Arushi Gahlot Saini; Savita Verma Attri; Bhavneet Bharti; Naveen Sankhyan; Prateek Bhatia
Journal:  Indian J Pediatr       Date:  2020-07-04       Impact factor: 1.967

3.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

Review 4.  Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases.

Authors:  Susan J van Rensburg; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Armand V Peeters; Carel J van Heerden; Rajiv T Erasmus; Annalise E Zemlin; Merlisa C Kemp; Mariaan Jaftha; Aye Aye Khine; Felix C V Potocnik; Lindiwe Whati; Penelope Engel-Hills; Ronald van Toorn; Maritha J Kotze
Journal:  Metab Brain Dis       Date:  2021-03-12       Impact factor: 3.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.